Omeros Corporation

Equities

OMER

US6821431029

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
3.06 ^USD	+0.66%		-4.67%	-6.42%

Apr. 01	Tranche Update on Omeros Corporation's Equity Buyback Plan announced on April 1, 2024.	CI
Apr. 01	Omeros Corporation announces an Equity Buyback for $50 million worth of its shares.	CI

Omeros Corporation Reports Earnings Results for the First Quarter Ended March 31, 2021

May 10, 2021 at 04:13 pm EDT

Omeros Corporation announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced operating loss was USD 30.612 million compared to USD 23.677 million a year ago. Net loss was USD 35.090 million compared to USD 29.031 million a year ago. Basic loss per share from continuing operations was USD 0.57 compared to USD 0.53 a year ago.

Latest news about Omeros Corporation

Tranche Update on Omeros Corporation's Equity Buyback Plan announced on April 1, 2024.	Apr. 01	CI
Omeros Corporation announces an Equity Buyback for $50 million worth of its shares.	Apr. 01	CI
Omeros Swings to Q4 Net Loss; Q1 Outlook Set	Apr. 01	MT
Omeros Corporation Provides Earnings Guidance for the First Quarter of 2024	Apr. 01	CI
Transcript : Omeros Corporation, Q4 2023 Earnings Call, Apr 01, 2024	Apr. 01
Omeros Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Omeros Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 01	CI
North American Morning Briefing : Tech in Focus on -2-	Mar. 25	DJ
North American Morning Briefing : Investors -2-	Mar. 18	DJ
National Bank Raises DRI Healthcare Target to $22 on Omidria News, Guidance Increase	Feb. 01	MT
DRI Healthcare Trust Expands Royalty Entitlement on US Net Sales of Omidria, Updates Deployment and CAGR Guidance	Feb. 01	MT
Omeros Corporation(NasdaqGM:OMER) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
North American Morning Briefing : Stock Futures -2-	Nov. 13	DJ
Transcript : Omeros Corporation, Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Omeros Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Omeros Corporation authorizes a Buyback Plan.	Nov. 08	CI
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting	Nov. 02	CI
Novartis drug candidate scores interim win in rare kidney disease trial	23-10-30	RE
Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer	23-10-19	CI
US Equity Markets Close Higher Monday on Expectations for Upbeat Q3 Earnings	23-10-16	MT
Sector Update: Health Care Stocks Rise Late Afternoon	23-10-16	MT
Sector Update: Health Care	23-10-16	MT
Top Midday Decliners	23-10-16	MT
Omeros to Discontinue Phase 3 Trial of Narsoplimab After Failing to Reach Statistical Significance in Reducing Proteinuria	23-10-16	MT
Transcript : Omeros Corporation - Special Call	23-10-16

Chart Omeros Corporation

Duration

Period

More charts

Company Profile

Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Companyâs lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

3.06

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
OMEROS CORPORATION	-6.42%	177M
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	103B
REGENERON PHARMACEUTICALS, INC.	+1.41%	95.71B
ARGENX SE	+0.84%	22.02B
BIONTECH SE	-17.84%	20.9B
GENMAB A/S	-9.23%	17.85B
WUXI APPTEC CO., LTD.	-42.83%	16.21B
BEIGENE, LTD.	-17.63%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.86B
SAREPTA THERAPEUTICS, INC.	+32.11%	12.04B

Bio Therapeutic Drugs